Bioventus Launches Durolane OA Treatment in Taiwan

By Julie A. Vetalice

Bioventus launched its DUROLANE® single-injection hyaluronic acid-based osteoarthritis (OA) treatment in Taiwan, to be marketed by Eulogiums for mild to moderate knee OA.

Bioventus' orthobiologic products are now available in six countries in the Asia Pacific region.

Source: Bioventus LLC

In 1Q14, Bioventus acquired ex-U.S. DUROLANE assets from Galderma, which still manufactures the product.

Product Labels: Viscosupplement

Tags: Product Launch